Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Moodys
Merck
Mallinckrodt
Colorcon

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dalcetrapib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Dalcetrapib: Sponsors, patents, clinical trial progress

Dalcetrapib is an investigational drug.

There have been 13 clinical trials for Dalcetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Myocardial Ischemia, Heart Diseases, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche, Medpace, Inc., and Dr. Reddy's Laboratories Limited.

There are one hundred and fifty-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Dalcetrapib
TitleSponsorPhase
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACSMedpace, Inc.Phase 3
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACSRoche Molecular Systems, IncPhase 3
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACSThe Montreal Health Innovations Coordinating Center (MHICC)Phase 3

See all Dalcetrapib clinical trials

Clinical Trial Summary for Dalcetrapib

Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib

See all Dalcetrapib clinical trials

US Patents for Dalcetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dalcetrapib   See Pricing Pharmaceutical compositions with enhanced performance and improved processability HERCULES LLC (Wilmington, DE)   See Pricing
Dalcetrapib   See Pricing CETP activity inhibitors Japan Tobacco Inc. (Tokyo, JP)   See Pricing
Dalcetrapib   See Pricing Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)   See Pricing
Dalcetrapib   See Pricing CETP activity inhibitor Japan Tobacco Inc. (Tokyo, JP)   See Pricing
Dalcetrapib   See Pricing Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE)   See Pricing
Dalcetrapib   See Pricing Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors Pfizer Inc. (New York, NY)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dalcetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Dalcetrapib Brazil 112015021179 2033-03-01   See Pricing
Dalcetrapib Canada 2899546 2033-03-01   See Pricing
Dalcetrapib China 105073783 2033-03-01   See Pricing
Dalcetrapib European Patent Office 2961775 2033-03-01   See Pricing
Dalcetrapib Japan 2016510080 2033-03-01   See Pricing
Dalcetrapib Japan 6456849 2033-03-01   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Boehringer Ingelheim
Dow
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.